Anavex Life Sciences
Develops oral investigational therapies for neurodegenerative and neurodevelopmental diseases.
Something off on this page? Send us feedback.
Profile
Develops oral investigational therapies for neurodegenerative and neurodevelopmental diseases, led by blarcamesine. The pipeline remains clinical-stage and pre-revenue, with no marketed therapy.
Built from a former online-photofinishing business, the company pivoted to drug development. It develops oral, investigational therapies for neurodegenerative and neurodevelopmental diseases, with blarcamesine as its central clinical candidate. Programs include Alzheimer’s disease, Parkinson’s disease, and Rett syndrome.
Clinical studies, translational science, and regulatory pathways form its stated approach. A European marketing-authorisation application for blarcamesine in early Alzheimer’s received a negative CHMP opinion, and re-examination was requested.
Pre-revenue since inception, the business has no marketed therapy. It depends on clinical development, regulatory review, future commercialization routes or partnerships, and continued periodic-reporting compliance.
Company facts
Key statistics
Year to date −18.9% · Average volume (30d) 926.5K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Oct 24, 2025 | Jones Trading | Downgrade | Buy | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026Q3 FY26 | −$0.08 | −$0.03 | +62.5% | — | — | — | — |
| Aug 25, 2026Q3 FY26 | −$0.08 | −$0.08 | 0.0% | — | — | — | +14.47% |
| Aug 24, 2026Q3 FY26 | −$0.08 | −$0.06 | +25.0% | — | — | — | −4.01% |
| Aug 21, 2026Q3 FY26 | −$0.08 | −$0.06 | +25.0% | — | — | — | +3.51% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$12.5M | −$14.5M | −$10.8M | −$6.8M | −$6.5M | $6.7M | |
| Net income | −$11.2M | −$13.2M | −$9.8M | −$5.7M | −$5.3M | $7.9M | |
| Diluted EPS | −$0.13 | −$0.16 | −$0.11 | −$0.06 | −$0.06 | $0.09 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $118.3M · Total debt $0 · Total assets $120.1M · Shareholders' equity $112.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 92.67M · Float 89.78M · 96.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.06M | 8.69% | 13F | Aug 7, 2026 |
| Vanguard Capital Management | 4.66M | 5.03% | 13G | Jul 31, 2026 |
| Two Sigma Investments, LP | 3.05M | 3.29% | 13F | Aug 14, 2026 |
| Geode Capital Management, LLC | 2.41M | 2.60% | 13F | Aug 12, 2026 |
| State Street Corp | 1.92M | 2.07% | 13F | Aug 7, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Eli Lilly
FDA-approved early-Alzheimer's anti-amyloid therapy
- Biogen
Co-commercializes FDA-approved LEQEMBI for early Alzheimer's
- Acadia Pharmaceuticals
Markets FDA-approved DAYBUE for Rett syndrome
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anavex Life Sciences | $2.99 | +0.14% | $277.1M | — | — | — | — |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Acadia Pharmaceuticals | $29.17 | +0.18% | $4.98B | 13.1 | 32.7 | 4.4 | +16.4% |
| Median | 38.7 | 28.7 | 4.4 | +16.4% |